| 영문 | severe acute respiratory syndrome(SARS) | 한글 | 중증급성호흡증후군 |
|---|---|---|---|
| 설명 | 중국 광동 지역에서 가장 먼저 발생한 전염성호흡기병으로 세계보건기구(WHO)에서 ‘중증급성호흡증후군(SARS)'으로 명명했다. 섭씨 38도 이상의 고열과 기침, 호흡곤란, 저산소증, X선상의 폐렴증상 중 하나 이상의 증상이 나타나며, 두통, 근육통, 식욕부진, 피로감, 발진, 설사를 동반할 수 있다. 초기 증상은 감기와 비슷하지만 폐렴으로 발전하면 치명적일 수 있다. 현재 밝혀진 감염경로는 환자가 재채기나 기침할 때 내뿜는 침방울이고, 이것이 다른 사람의 호흡기로 들어갈 때 전염된다. 침방울이 전달되는 거리는 보통 1m로 보고 있다. 공기를 통해 전염이 가능하다는 주장이 제기됐지만 아직 확인되지 않았다. 원인균은 변종 코로나바이러스로 밝혀졌다. |
||
| AP | accessory pathway; accounts payable; acid phosphatase; acinar parenchyma; action potential; active p... |
|---|---|
| ACI | acceleration index; acoustic comfort index; acute cardiac ischemia; acute coronary infarction; acute... |
| AIE | acute inclusion-body encephalitis; acute infectious encephalitis; acute infective endocarditis |
| AIP | acute idiopathic pericarditis; acute infectious polyneuritis; acute intermittent porphyria; aldoster... |
| ARF | acute renal failure; acute respiratory failure; acute rheumatic fever; Addiction Research Foundation... |
acute allergic reaction (급성 과민성 반응
| cutaneous lupus erythematosus | Skin disease seen in patients with discoid form of lupus erythematosus, a term for a variety of skin lesions seen in systemic lupus erythematosus. (05 Mar 2000) |
|---|---|
| neonatal lupus | Lupus erythematosus occurring in newborn children of mothers who had lupus during pregnancy; anti-SSA antibodies usually should be screened for; 50% have anti-nuclear antibodies. A variety of skin lesions are seen, which can resolve or leave scarring; the syndrome usually resolves; however cardiac manifestations can be fatal. Some children develop systemic lupus later in life. (05 Mar 2000) |
| systemic lupus erythematosus | <immunology, nephrology, rheumatology> A disease of humans, probably autoimmune with antinuclear and other antibodies in plasma. Immune complex deposition in the glomerular capillaries is a particular problem. Acronym: SLE (19 Jan 1998) |
| discoid lupus erythematosus | A form of lupus erythematosus in which cutaneous lesions are present; these commonly appear on the face and are atrophic plaques with erythema, hyperkeratosis, follicular plugging, and telangiectasia; in some instances systemic lupus erythematosis may develop. Synonym: chronic discoid lupus erythematosus. (05 Mar 2000) |
| disseminated lupus erythematosus | <immunology, nephrology, rheumatology> A disease of humans, probably autoimmune with antinuclear and other antibodies in plasma. Immune complex deposition in the glomerular capillaries is a particular problem. Acronym: SLE (19 Jan 1998) |
| drug-induced lupus | <dermatology> An inflammatory autoimmune disorder, similar to lupus, that develops in response to the use of a particular medication. It is characterised by anti-histone antibodies. More benign than the usual disease, with less renal involvement. The syndrome clears after stopping the offending drug. Drugs that are known to cause this reaction include procainamide, isoniazid, sulphasalazine, hydralazine, methyldopa, phenytoin, chlorpromazine and penicillamine. The arthritis, cardiac, pulmonary and systemic features may be present, but the kidney involvement (nephritis) and neurologic disease are rare. Symptoms generally resolve spontaneously after stopping the medication. Complications include myocarditis, pericarditis, thrombocytopenic purpura and infections. (18 Jul 2002) |
| lupus | A systemic disease that results from an autoimmune mechanism. Individuals with lupus will produce antibodies to their own body tissues. The resultant inflammation can cause kidney damage, arthritis, pericarditis and vasculitis. (27 Sep 1997) |
| lupus anticoagulant | An immunoglobulin that interferes with blood coagulation and has antithromboplastin activity. This immunoglobulin can prolong blood clotting and occurs in approximately 25% of people with lupus. (27 Sep 1997) |
| lupus anticoagulants | Lupus anticoagulants are a common cause of a prolonged activated partial thromboplastin time (APTT) which is corrected by the addition of platelet -rich plasma (or phospholipids) and not by platelet-poor plasma. The methods of choice for detection of lupus anticoagulants are the kaolin clotting time using the rabbit brain neutralisation procedure and the dilute Russell viper venom test (dRVVT). Current data suggest that lupus anticoagulants and antibodies to negatively charged phospholipids (cardiolipin, phosphatidylserine, phosphatidic acid and phosphatidylinositol) are risk factors for arterial and venous thrombosis and for recurrent abortions in populations of patients which are distinct but overlapping. Drug-induced lupus anticoagulants are also associated with increased risk of thrombosis. Current testing for lupus anticoagulants and phospholipid antibodies (cardiolipin plus phosphatidylserine) may be useful for assessing risk in patients with systemic lupus erythematosus. Some data indicate that lupus anticoagulants assays are more reliable predictors of thrombosis, foetal loss and thrombocytopenia than are cardiolipin antibody (ACA) assays. Although the technology is in many ways more reliable, the rush to describe associations of lupus anticoagulants with various disorders has been much less scientifically unseemly than has been that of ACAs with their bewildering variety of clinical associations. The contribution of one serious study must, it seems, render tolerable the excess of trivia recently published in this area. See also cardiolipin antibodies and phospholipid antibodies. (05 Mar 2000) |
| lupus band test | A direct immunofluorescent technique for demonstrating a band of immunoglobulins at the dermal-epidermal junction of the skin of patients with lupus erythematosus. (05 Mar 2000) |
| lupus coagulation inhibitor | An antiphospholipid antibody found in association with systemic lupus erythematosus (lupus erythematosus, systemic), antiphospholipid syndrome, and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including foetal death and spontaneous abortion, as well as a variety of haematologic and neurologic complications. (12 Dec 1998) |
| lupus erythematodes | Skin disease in which there are red scaly patches, especially over the nose and cheeks. May be a symptom of systemic lupus erythematosus. (18 Nov 1997) |
| lupus erythematosus | Skin disease in which there are red scaly patches, especially over the nose and cheeks. May be a symptom of systemic lupus erythematosus. (18 Nov 1997) |
| lupus erythematosus cell | <pathology> Phagocyte that has ingested nuclear material of another cell: characteristic of systemic lupus erythematosus. (18 Nov 1997) |
| lupus erythematosus cell test | <investigation> A test for lupus that measures the presence of autoantibodies against nuclear proteins in the blood. Performed on a normal venipuncture specimen, this test is positive in 70 to 80% of patients with lupus. Some patients with rheumatoid arthritis, scleroderma and drug-induced lupus may also have a positive test result. (27 Sep 1997) |